The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells

Prostaglandins and Other Lipid Mediators

Volumn 83, Issue 3 SPEC. ISS., 2007, Pages 231-236

  Shen, Huang Wei ^a   Chen, Yu Lin ^a   Chern, Ching Yuh ^b   Kan, Wai Ming ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Beraprost; BMY 45778; Human erythroleukemia cells; Megakaryocytopoesis; Prostacyclin

Indexed keywords

BERAPROST; BUCLADESINE; CYCLIC AMP; FIBRINOGEN RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PROSTAGLANDIN E2; SULPROSTONE; [3 [4 (4,5 DIPHENYL 2 OXAZOLYL) 5 OXAZOLYL]PHENOXY]ACETIC ACID;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL SIZE; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; POLYPLOIDY;

EID: 34247483420     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.01.012     Document Type: Article

References (14)

1. Caen J.P., Han Z.C., Bellucci S., and Alemany M. Regulation of megakaryocytopoeisis. Haemostatsis 29 (1999) 27-40
2. Long M.W., Heffner C.H., Williams J.L., Peters C., and Prochownick E.V. Regulation of megakaryocytic phenotype in human erythroleukemia cells. J Clin Invest 85 (1990) 1072-1084
3. Roth B.J., Sledge G.W., Straena J.E., Brandt J., Goheen M., and Hoffman R. Analysis of phorbol ester stimulated human megakaryocyte development. Blood 72 (1988) 202-207
4. Papayannopoulou T., Nakamoto B., Kurachi S., and Nelson R. Analysis of the erythroid phenotype of HEL cells: clonal variation and the effect of inducers. Blood 70 (1987) 1764-1772
5. Long M.W., Hutchinson R.J., Gragowski L.L., Heffner C.H., and Emerson S.G. Synergistic regulation of human megakaryocyte colony formation. J Clin Invest 82 (1988) 1779-1786
6. García P., and Calés C. Endoreplication in megakaryoblastic cell lines is accompanied by sustained expression of G1/S cyclins and down regulation of cdc25C. Oncogene 13 (1996) 695-703
7. Tabilio A., Rosa J.P., Testa V., et al. Expression of platelet membrane glycoproteins and alpha-granule proteins by a human erythroleukemia cell line (HEL). EMBO J 3 (1984) 453-459
8. Ii M., Hoshiga M., Fukui R., et al. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). Cardiovasc Res 52 (2001) 500-508
9. Martin P., and Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216 (1982) 1233-1235
10. 3 signaling. J Cell Biol 147 (1999) 1419-1429
11. Seiler S.M., Brassard C.L., Federici M.E., Romine J., and Meanwell N.A. 3-[[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins 53 (1997) 21-35
12. Murray R., Furci L., and FitzGerald G.A. Induction of prostacyclin receptor expression in human erythroleukemia cells. FEBS 255 (1989) 172-174
13. Zauli G., Bassini A., Catani L., et al. PMA-induced megakaryocytic differentiation of HEL cells is accompanied by striking modifications of protein kinase C catalytic activity and isoform composition at the nuclear level. Br J Haematol 92 (1996) 530-536
14. Abramovitz M., Adam M., Boie Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483 (2000) 285-293